ERLEADA®

(apalutamide) 
JOHNSON & JOHNSON 
HK Reg. No. HK-68966 (26 Jan, 2026)   

Composition²:
ERLEADA^® is available as 60 mg film-coated tablets

Indication²:
ERLEADA^® is indicated:
•In adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease
•In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

References

2. EMA. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf. [Accessed 9 March 2026].